Athanor Capital, LP Apellis Pharmaceuticals, Inc. Transaction History

Athanor Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$40.8 - $57.39 $186,252 - $261,985	-4,565 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $66,260 - $123,094	-2,152 Reduced 32.04%	4,565 $261,000
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $82,511 - $107,242	-3,187 Reduced 32.18%	6,717 $203,000
Q2 2020 Aug 13, 2020	BUY	$24.8 - $38.49 $245,619 - $381,204	9,904 New	9,904 $323,000
Q1 2020 May 14, 2020	SELL	$17.91 - $44.33 $291,933 - $722,579	-16,300 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$22.1 - $30.8 $181,220 - $252,560	-8,200 Reduced 33.47%	16,300 $499,000
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $224,037 - $299,274	9,300 Added 61.18%	24,500 $590,000
Q2 2019 Aug 13, 2019	BUY	$18.0 - $25.34 $273,600 - $385,168	15,200 New	15,200 $385,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.